Core Scientific, Inc/tx Form 4 insider transactions

Core Scientific Director Jeffrey David Booth was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Jordan Levy was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Elizabeth Crain was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Yadin Rozov was granted 18,575 restricted stock units, vesting in February 2027.

Core Scientific director Eric Stanton Weiss was granted 18,575 restricted stock units, aligning his interests with long-term shareholder value.

Core Scientific's CEO, Adam Taylor Sullivan, filed an amended Form 4 to correct the number of shares withheld for tax obligations related to restricted stock unit vesting.

Core Scientific CEO Adam Taylor Sullivan disposed of 274,404 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Core Scientific CEO Adam Taylor Sullivan reported an increase in beneficial ownership through RSU vesting and an in-kind distribution, alongside a sale to cover tax obligations.

Core Scientific's Chief Legal and Administrative Officer, Todd DuChene, acquired 55,758 performance-based restricted stock units and disposed of 139,873 shares to cover tax obligations, resulting in a net decrease in his beneficial ownership.

Core Scientific director Yadin Rozov reported a charitable donation of 40,100 shares of common stock.

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, reported a charitable donation of 20,000 Tranche 1 Warrants.

Core Scientific Director Yadin Rozov purchased 30,000 Tranche 1 Warrants, signaling confidence in the company's future.

Core Scientific Director Eric Stanton Weiss purchased 5,000 shares of common stock at $21.50 per share, increasing his beneficial ownership to 226,687 shares.

CoreWeave Inc. urges Core Scientific stockholders to vote FOR its proposed all-stock acquisition, disagreeing with proxy advisor recommendations.

Core Scientific provides supplemental disclosures for its merger with CoreWeave to address shareholder lawsuits challenging proxy statement information.

CoreWeave, Inc. filed a Form 425 communication regarding its proposed acquisition of Core Scientific, Inc., directing investors to key SEC documents.

CoreWeave reaffirms its 'best and final' all-stock offer for Core Scientific, refuting a hedge fund's claims and highlighting significant benefits.

Core Scientific's Board unanimously recommends an all-stock merger with CoreWeave, citing significant pro forma benefits and a 71% premium for stockholders.

Core Scientific's Board unanimously recommends stockholders vote for the all-stock merger with CoreWeave, citing significant pro forma benefits and de-risked execution.

CoreWeave CEO discusses significant AI infrastructure deals, high client win rates, and the strategic Core Scientific acquisition.

CoreWeave's CEO discusses strategic acquisitions, significant power capacity expansion, and robust demand for AI infrastructure and software solutions.

CoreWeave's CEO, Michael Intrator, posted a LinkedIn update regarding the proposed acquisition of Core Scientific, referencing key SEC filings and associated risks.

CoreWeave, Inc. announced the filing of key documents with the SEC related to its proposed acquisition of Core Scientific, Inc., including an effective Form S-4 and a definitive proxy statement.

CoreWeave CEO Michael Intrator confirmed the company will not increase its $9 billion acquisition offer for Core Scientific despite investor objections.

Core Scientific's Chief Legal and Administrative Officer, Todd M. Duchene, reported a disposition of shares to cover tax obligations related to restricted stock unit vesting.

Core Scientific CEO Adam Taylor Sullivan reported a planned disposition of 23,508 shares of common stock to cover tax obligations related to restricted stock unit vesting on September 30, 2025.

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, disposed of 11,805 shares of common stock to cover tax withholding obligations.

CoreWeave's CEO Michael Intrator discusses the strategic rationale behind the $9 billion all-stock acquisition of Core Scientific, emphasizing vertical integration for enhanced AI infrastructure delivery and immediate margin benefits.

CoreWeave, Inc. has filed a Form 425 communication with the SEC regarding its proposed acquisition of Core Scientific, Inc., emphasizing the importance for investors to review comprehensive transaction documents.

CoreWeave, Inc. has announced its proposed acquisition of Core Scientific, Inc., outlining the necessary SEC filings and potential risks associated with the transaction.